Tollip Inhibits IL-33 Release and Inflammation in Influenza A Virus-Infected Mouse Airways
Journal of Innate Immunity · 2023 · 15 (1) · 67-77
DOI: 10.1159/000525315 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Innate Immunity, online erschienen am 27.06.2022. Verfasst von Niccolette Schaunaman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, National Jewish Health, Denver, Colorado, USA. Hauptthemen laut MEDLINE: Asthma, Influenza A virus, Influenza, Human, Orthomyxoviridae Infections. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Respiratory influenza A virus (IAV) infection continues to pose significant challenges in healthcare of human diseases including asthma. IAV infection in mice was shown to increase IL-33, a key cytokine in driving airway inflammation in asthma, but how IL-33 is regulated during viral infection remains unclear. We previously found that a genetic mutation in Toll-interacting protein (Tollip) was linked to less airway epithelial Tollip expression, increased neutrophil chemokines, and lower lung function in asthma patients. As Tollip is involved in maintaining mitochondrial function, and mitochondrial stress may contribute to extracellular ATP release and IL-33 secretion, we hypothesized that Tollip downregulates IL-33 secretion via inhibiting ATP release during IAV infection. Wild-type and Tollip knockout (KO) mice were infected with IAV and treated with either an ATP converter apyrase or an IL-33 decoy receptor soluble ST2 (sST2). KO mice significantly lost more body weight and had increased extracellular ATP, IL-33 release, and neutrophilic inflammation. Apyrase treatment reduced extracellular ATP levels, IL-33 release, and neutrophilic inflammation in Tollip KO mice. Excessive lung neutrophilic inflammation in IAV-infected Tollip KO mice was reduced by sST2, which was coupled with less IL-33 release. Our data suggest that Tollip inhibits IAV infection, potentially by inhibiting extracellular ATP release and reducing IL-33 activation and lung inflammation. In addition, sST2 may serve as a potential therapeutic approach to mitigate respiratory viral infection in human subjects with Tollip deficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, National Jewish Health, Denver, Colorado, USA.
- Department of Biological Sciences, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, USA.
- Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona, USA.
Förderung
- NIAID NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Schaunaman, N., Dimasuay, K. G., Cervantes, D., Li, L., Numata, M., Kraft, M., & Chu, H. W. (2023). Tollip Inhibits IL-33 Release and Inflammation in Influenza A Virus-Infected Mouse Airways. Journal of Innate Immunity, 15(1), 67-77. https://doi.org/10.1159/000525315
Vancouver
Schaunaman N, Dimasuay KG, Cervantes D, Li L, Numata M, Kraft M, et al. Tollip Inhibits IL-33 Release and Inflammation in Influenza A Virus-Infected Mouse Airways. Journal of Innate Immunity. 2023;15(1):67-77. doi:10.1159/000525315
BibTeX
@article{Schaunaman2023,
author = {Schaunaman, Niccolette and Dimasuay, Kris Genelyn and Cervantes, Diana and Li, Liwu and Numata, Mari and Kraft, Monica and Chu, Hong Wei},
title = {Tollip Inhibits IL-33 Release and Inflammation in Influenza A Virus-Infected Mouse Airways},
journal = {Journal of Innate Immunity},
year = {2023},
volume = {15},
number = {1},
pages = {67--77},
doi = {10.1159/000525315}
}
EUVIMED